Table 4. Selected hematological and extra‐hematological adverse events occurring during treatment in the 99 patients undergoing at least 1 cycle of CHTa.

^aNumbers outside parentheses represent the proportion of all patients in the cohort (N=99) developing adverse events; the percentage reported inside parentheses refers to the occurrence of adverse events in the cohort of patients treated with liposomal doxorubicin (N = 39).

Abbreviations: CHT, chemotherapy; DLBCL, diffuse large B‐cell lymphoma.